Home Up Feedback Contents Search Sell your Prod. Meet us News           

 
Home • Up

Diagnostics of Allergy and Foord Intolerance

 

Home

GENTAUR

+32 1658 9045

or

0032 (0)16 41 44 07

+32 1650 9045

info@gentaur.com

Av. de l' Armée 68

B-1040 Brussels

BELGIUM

France

tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 Paris

Italia

tel 02 36 00 65 93

fax 02 36 00 65 94

20135 Milano

Deutschland

tel +32 1658 9045

fax +32 1650 9045

Polska

Tel 058 710 33 44

Fax 00 32 16 50 90 45

ul. Grunwaldzka 88A/2

81-771 Sopot

日本

tel +81 78 386 0860

fax +81 78 306 0296

Minaatojimaminami-manchi

Chuo-ku, Kobe

065-0047

Österreich
+43720880899

Canada Montreal
+15149077481

Česká republika Praha
+420246019719

Danmark
+4569918806

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494

Magyarország Budapest
+3619980547

Ireland Dublin
+35316526556

Luxembourg
+35220880274

Nederland
+31208080893

Norge Oslo
+4721031366

Polska Warszawa
+48223988221

Sverige Stockholm
+46852503438

Schweiz Züri
+41435006251

US New York
+17185132983

Other Countries
0032 (0)16 41 44 07


 

 

 

 

 

Clonagen

Gentaur

Genprice

Bioxys

Labprice

K200            K180            K181            K160            K161

 

K200 Total IgE EIA

Total immunoglobulin E (IgE) serum level is widely reported as the laboratory marker of atopic diseases
such as atopic asthma, atopic dermatitis, and pollenosis. Separately, high levels of total serum IgE
are characteristic for parasitic infestations and some other clinical disorders including superficial and
systemic mycosis. Decreased levels of IgE are found in cases of hypogammaglobulinemia, autoimmune
diseases, ulcerative colitis, and primary biliary cirrhosis.
In allergic patients, serum total IgE level in general corresponds to the severity of the allergic disease
and may be therefore used for monitoring of all kinds of anti-allergic therapy or allergen elimination.

 

Sample type: serum, plasma                             Incubation: 30’/30’/15’, 370С                 Control sample: 1
Sample volume: 50 μl                                       Calibrators: 5 (0-1000 IU/ml)                 Shelf life: 12 months
Sensitivity: 6 IU/ml                                         Normal range, IU/ml: <130
 

 

K180 Gliadin IgG EIA
K181 Gliadin IgA EIA


Celiac disease (CD) or gluten-sensitive entheropathy is a chronic disease characterized by impared
intestinal absorption due to mucosal lesions. The exact ethiology of CD is unknown but it is clearly
shown that gliadin - the alcohol soluble fraction of wheat gluten - is the toxic agent. High concentrations
of antigliadin antibodies (AGA) found in blood, saliva and intestinal secretions are characteristic for untreated
celiac patients. These antibodies gradually disappear after gluten exclusion from the patient’s diet.
AGA testing is a simple and inexpensive method to efficiently select candidates for mucosal biopsy of the
duodenal-jejunal junction, the latter method being essential for the confirmation of the diagnosis of CD.
Early detection of AGA in high risk populations would contribute to prevent the insidious consequences
of chronic malabsorption. Individuals at risk include short-stature children, unexplained anemia,
unexplained hypocalciemia or osteomalacia, delayed puberty, insulin-dependent diabetes mellitus,
autoimmune thyroiditis and selective IgA deficiency. It is well established that IgA-AGA are more
specific than IgG-AGA. Nevertheless, combined IgG/IgA screening might be more effective since there
is an unexplained but clear association between CD and selective IgA deficiency.
In treated celiac patients without this deficiency IgA-AGA is the test of choice for monitoring diet
compliance. Serum IgA-AGA level responds very quickly to the admission of gluten-free diet (levels
drop below the cut-off level within two to six months) while IgG-AGA may take more than one year to
become negative; breaking the diet causes more prompt elevation of IgA-AGA compared to IgG-AGA.
Herpetiform dermatitis is a disease entity strongly associated to gluten-sensitive enteropathy, and AGA
serology is not capable to distinguish between these two diseases.
Separately, there are well reported clinical conditions showing positive IgG-AGA and, rarely, IgA-AGA
non-related to histologically proven CD, eg all kind of malapsortion syndromes, including Crohn’s
disease, ulcerative colitis, galactosidase deficiency, post-infection malapsorption etc. The patients
with rheumatoid arthritis, Sjogren syndrome, systemic sclerosis and other connective tissue diseases
show abnormally high prevalence of moderately elevated gliadin IgA and IgG. These findings may be
considered as non-relevant to GI pathology; however, gliadin free diet may be implemented for their
treatment.
According to data obtained by Xema, first degree relatives of CD children patients (especially their
parents) show very frequent positivity for both IgG-AGA and IgA-AGA while displaying virtually no
symptoms of gastrointestinal diseases, herpetiform dermatitis, or other diseases supposed to cause
this positivity.
Test flowchart, sensitivity, calibrators and normal ranges are the same in both kits (please, see below).

 

Sample type: serum, plasma                             Sensitivity: 10 U/ml                             Control sample: 1
Sample predilution: 1:101                                 Incubation: 30’/30’/15’, RT                    Shelf life: 12 months
Sample volume: 100 μl                                     Calibrators: 5 (0-200 U/ml)                   Normal range, U/ml: <25

 


K160 Anti-tTG IgG EIA                                                                                             New kit!
K161 Anti-tTG IgA EIA                                                                                             New kit!


Celiac disease (CD) is a serious, lifelong, gastrointestinal disorder that can cause a wide spectrum
of clinical symptoms in children and adults. CD patients are unable to digest gluten, present in all
crops, especially in wheat, barley and rye.The classic symptoms are diarrhea, abdominal distension,
weight loss and malnutrition. Those symptoms were often misdiagnosed and interpreted to be due
to gastroenteritis, food allergy, viral or other infection, anemia, stress, nervous condition, irritable
bowel and food allergy. For this reason the proper diagnosis of CD could take several years.
The various serological tests employed in the work-up of patients suspected to have CD include antigliadin
antibody (AGA), anti-endomysial antibody (EMA), anti-reticulin antibody (ARA) and anti-tissue
transglutaminase (tTG) antibody tests. Antibodies to gliadin and tTG are detected by ELISA, whereas
endomysium and reticulin antibodies are detected by indirect immunofluorescence.
EMA are very specific indicators of CD. However, the EMA test is an immunohistochemical method that
requires experience in reading immunofluorescence reactions.
Since identification of tTG as the endomysial antigen, ELISA methods have been described for detecting
antibodies in the sera of patients with CD. The advantage of the anti-tTG antibody assay is that it is less
subjective than EMA and more accurate than AGA assay. In various studies on the efficacy of the antitTG
antibody method for screening for CD, the specificity and sensitivity of this method has been found
to range from 90 percent to 95 percent. Anti-tTG antibodies also quickly disappear after admission
of gluten-free diet (within 6 months). Test flowchart, sensitivity and calibrators are the same in both
kits (please, see below).

 

Sample type: serum,                              Sensitivity: 5 U/ml                              Control sample: 1
Sample predilution: plasma 1:101            Incubation: 30’/30’/15’, 370С                Shelf life: 12 months
Sample volume: 100 μl                           Calibrators: 6 (0-200 U/ml)                   Normal range, U/ml: <20 (IgA), <30 (IgG)
 

 

Send mail to webmaster@gentaur.com with questions or comments about this web site.
Copyright © 2002 GENTAUR Molecular Products
Last modified: 05/29/09